What is MicroSynbiotiX?
MicroSynbiotiX is at the forefront of developing advanced technological solutions aimed at drastically reducing the reliance on antibiotics in farmed fish. Leveraging breakthroughs in algal genomics and molecular biology, the company engineers microalgae to express cost-effective therapeutic proteins and vaccines. This novel application of microalgae as an oral delivery system significantly lowers labor and production expenses, making effective vaccines more accessible and user-friendly. The company's technology promises to eliminate antibiotic use, decrease mortality rates in aquaculture, prevent devastating disease outbreaks, and bolster global food security. Founded in 2016 and based in Cork City, Ireland, MicroSynbiotiX is positioned to revolutionize the aquaculture industry.
How much funding has MicroSynbiotiX raised?
MicroSynbiotiX has raised a total of $1.2M across 1 funding round:
Angel/Seed
$1.2M
Angel/Seed (2017): $1.2M, investors not publicly disclosed
What's next for MicroSynbiotiX?
The substantial enterprise-level funding and recent strategic investment provide MicroSynbiotiX with the necessary capital to scale its operations and further develop its proprietary technology. This backing is expected to accelerate the commercialization of its microalgae-based solutions, potentially leading to wider adoption across the global aquaculture sector. The company's focus on sustainability and disease prevention aligns with increasing market demands for responsible food production, positioning MicroSynbiotiX for significant future growth and impact in enhancing global food security.
See full MicroSynbiotiX company page
